Immune-mediated mechanisms are thought to play a key role in the development of coronary artery disease and its thrombotic complications. Preinfarction angina has been suggested to improve left ventricular function and short-term outcomes.
Some publications have indicated that other components of the immune system such as immunoglobulins and complement are involved in acute coronary syndromes. [4] [5] [6] [7] [8] Elevated immunoglobulin E (IgE) levels in particular have been suggested to protect patients with acute myocardial infraction (AMI) from its complications 9, 10) . Brief periods of myocardial ischemia before the onset of an acute myocardial infarction have been indicated to improve left ventricular function and shortterm outcomes. [11] [12] [13] [14] [15] The exact mechanism of this protective effect is not known, but several mechanisms have been proposed to explain these benefits. The potential mechanisms that have been suggested include ischemic preconditioning, enhanced thrombolysis, protection from ventricular fibrillation, reduced risk of no-reflow phenomenon, and collateral blood flow. 11, 12, [16] [17] [18] [19] However, the relationship between preinfarction angina and immunoinflammatory mechanisms has not been investigated adequately.
The purpose of the present study was to investigate the relation between the immune response and in-hospital clinical course in preinfarction angina.
METHODS
Patient selection : We prospectively evaluated 93 consecutive eligible patients admitted to our hospital between December 1999 and May 2000 with a diagnosis of a first AMI. Forty-three patients (mean age, 58.1 ± 10.7 years) exhibited preinfarction angina within 24 hours before the onset of AMI (preinfarction angina group) and fifty patients (mean age, 58.5 ± 9.0 years) were free from preinfarction angina (sudden onset group). We selected the first myocardial infarction as an inclusion criteria to avoid confusional bias in patients with a history of ischemic chest pain. Myocardial infarction was diagnosed when the following criteria were fulfilled; 1) typical chest pain lasting > 30 minutes; 2) ST segment elevation at least 0.2 mV in at least two contiguous leads on the standard 12-lead electrocardiogram, and 3) a serum creatine kinase-MB concentration more than twice the upper limit of normal (25 IU/liter in our laboratory). Patients with previous MI, according to patient history and electrocardiographic evidence, admission more than 6 hours after the onset of symptoms, contraindication to thrombolytic therapy, known inflammatory conditions likely to be associated with an acute phase response, and neoplastic disease were excluded from the study. All patients participating in the study gave their informed consent after receiving oral and written information. Hospital data collection: The following data were obtained; age, sex, cigarette smoking during the preceding two years, hypertension as defined by the JNC VI, 20) diabetes mellitus as defined by the WHO Study Group. 21) hypercholester-
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No 2 olemia, a total cholesterol level above 220 mg/dL, and the presence of preinfarction angina. A history of preinfarction angina was obtained from the patients themselves on admission and was reconfirmed by two or more attending cardiologist within a few days of admission. Preinfarction angina was defined as the presence of typical transient chest pain, within 24 hours before the onset of AMI, occurring at rest or during exercise. Sudden onset MI was defined as cases including all AMI criteria during our clinical evaluation, but they had no previous cardiac complaints. The onset of AMI was defined as the initiation of cardiac symptoms persisting for >30 minutes. A patient was excluded from the study if he or she was unable to provide a clear clinical history.
All patients who visited the hospital were transferred to the intensive coronary care unit. They were followed for 3-7 days (mean, 4.7 days) in a standard intensive care setting. All patients received intravenous thrombolytic agents (streptokinase 1.5 million units as a continuous infusion over 1 hour or t-PA 15 mg as a bolus followed by 50 mg as a continuous infusion over 30 minutes and 35 mg in 1 hour). Pharmacological treatment included heparin, beta blocker, lipid lowering therapy, and aspirin if not contraindicated. Other medications were given according to the decisions of the physician. The incidence of complications (heart failure, recurrent angina after MI, and coronary interventions) and in-hospital mortality were compared between patients with and without preinfarction angina. Heart failure was defined as class II or greater according to Killip's classification. 22) Postinfarction angina was diagnosed in the presence of new angina pectoris within two weeks after myocardial infarction. We also evaluated the occurrence of severe arrhythmias such as sustained ventricular tachycardia, ventricular fibrillation, and complete heart block. Echocardiography: Standard echocardiography, including Doppler studies, was performed (ATL-5000, Advance Technology Laboratories, Bothell, WA, USA). The left ventricular ejection fraction calculated with a modified Simpson method and left ventricular wall motion were assessed based on the American Society of Echocardiography recommendations.
23)
Coronary angiography: Forty-four patients underwent coronary angiography without exercise stress testing because of post-MI angina or class II or greater according to Killip's classification. The remaining patients underwent submaximal exercise stress testing based on a modified Bruce protocol within 3-5 days, of whom 33 had no angina, ST segment changes, or hypotension during exercise stress testing, and therefore, coronary angiography was not performed in these patients. A total of 60 patients underwent coronary angiography during the inhospital period, 26 had preinfarction angina, and 34 had sudden onset AMI. Selective coronary angiography in a multiple projection was performed using the Judkins technique. Significant coronary artery disease was defined as a > 50% narrowing of the luminal diameter of a major epicardial vessel. Evaluations were made by two invasive cardiologists who had no knowledge of the clinical characteristics of the patients. If there were differences, they were resolved by consensus between the two observers. Biochemical and other laboratory parameters: Venous blood samples were obtained from an antecubital vein immediately after admission to the hospital. Leukocyte count was determined with on automated Coulter STKS counter. Serum cholesterol was determined using a full enzymatic CHOD-PAP method (Boehringer-Mannheim, Mannheim, Germany). Fibrinogen levels were determined using mechanical cold detection (ST4 coagulation analyzer-Diagnostica Stago). Immunoglobulins, CRP, and complement were measured by nephelometric methods (BN ProSpec System, Dade Behring, Malburg, Germany). Troponin I levels were measured by a two-side chemiluminescent enzyme immunometric assay (Immulite-2000, Diagnostic Products Corporation, Cardiff, Wales). Statistical analysis: Statistical analysis was performed with SPSS (Scientific Packages for Social Sciences, Inc, Chicago, IL, USA) for Windows, version 11.0. Comparisons between two groups were made using an independent sample T test. Nonparametric value comparisons between two groups were conducted using the Mann-Whitney U test. All data are presented as the mean ± SD. A P < 0.05 was considered statistically significant. Table I summarizes the characteristics and infarct size parameters of the patients. The two groups did not differ in terms of diabetes mellitus, smoking habits, or heredity. However, there were significantly more men in the sudden onset group than in the preinfarction angina group (P < 0.05). Hypertension was present in 26% of the preinfarction angina group and in 48% of the sudden onset Values are expressed as the mean ± SD and numbers (percentages). LVWMAI = left ventricular wall motion abnormality index. group, and this difference was significant (P < 0.005). Dyslipidemia was present in 49% of the preinfarction angina group and in 26% of the sudden onset group, and this difference also was significant (P < 0.001).
RESULTS
Angiographic data and in-hospital complications are shown in Table II . Compared to the sudden onset group, the preinfarction angina group had a significantly lower incidence of single vessel disease (P < 0.05). Two and three vessel disease did not differ between the two groups. The incidence of heart failure was lower in the preinfarction group than in the sudden onset group (P < 0.005). Malignant arrhythmias after hospitalization were less frequent in the preinfarction group than in the sudden onset group (P < 0.05). Post-MI angina did not differ between the two groups. Seven patients died in the hospital. Two were from the preinfarction angina group, while the remaining were from the sudden onset group. This difference was not statistically significant.
Laboratory parameters are presented in Table III . The preinfarction angina group and the sudden onset group did not differ with respect to erythrocyte sedimentation rate, fibrinogen, immunoglobulin-G, immunoglobulin-M, immunoglo- bulin-A, and complement-3 (C3). White blood cell count and CRP were significantly lower in the preinfarction angina group than in the sudden onset group (P < 0.001, P < 0.005, respectively) (Figures 1 and 2) . Conversely, IgE and complement-4 (C4) were significantly higher in the preinfarction angina group than in the sudden onset group (P < 0.001, P < 0.001, respectively), (Figures 3  and 4) . 
DISCUSSION
In the present study, preinfarction angina was associated with a lower incidence of arrhythmias and heart failure. Moreover, patients with preinfarction angina were more likely to have lower troponin-I, levels and to have a better ejection fraction compared with sudden onset AMI. The findings clinically support a protective role for preinfaction angina. Several studies have shown a good clinical outcome in patients with preinfarction angina, especially when thrombolytic therapy was given. 10, 24, 25) The beneficial effect that was observed in most of the studies on preinfarction angina has been explained in terms of mechanisms such as ischemic preconditioning, thrombus formation, less resistance to fibrinolysis, and collateral development. 10, [26] [27] [28] There were no differences between the groups for risk factors such as age, diabetes, smoking, and heredity. Hypertension was a more evident risk factor in the sudden onset group. Dyslipidemia was seen more frequently in the preinfarction angina group. In the coronary vascular bed, while oxide LDL stimulates the immune response, hypertension causes more prominent mechanical changes.
3) Single vessel disease was observed more commonly in the sudden onset group according to the angiographic data, while no significant difference was observed between the groups with respect to two vessel disease and three vessel disease.
Nowadays, it is generally accepted that the immunoinflammatory system has an important role in the development of acute coronary syndromes. Moreover, basic components of the immune system such as CRP and white blood cells are used to determine the prognosis of a patient with myocardial infarction. 1, 2, 29, 30) Since a high white blood cell count and elevated CRP levels are associated with a poor prognosis in patients with myocardial infarction, they are also related to the severity of the immune response. CRP receptors are expressed on white blood cells and an activation of the complement cascade by CRP has been reported. 31) Some studies have discussed the important role of other molecules in the immune system, such as complement and immunoglobulins, in acute coronary syndromes. 5, 32, 33) Local and systemic production of complement increases, especially in ischemia-reperfusion. In acute coronary syndromes, complement becomes activated by both classical and alternative routes, and forms a membrane attack complex with CRP and then mediates myocardial cell necrosis. The soluble form of the terminal membrane attack complex is detectable in plasma and increased levels have been demonstrated in patients with AMI. [4] [5] [6] In the present study, although both the preinfarction angina group and sudden onset group had acute coronary syndrome, complement tended to increase more in the preinfarction angina group. This increase was statistically significant for the serum level of C4. High serum levels of complement are an indicator of a low grade immunoinflam-Vol 45 No 2 matory response. CRP stimulates the 'omplement cascade via the classical pathway. 4) Consequently, complement is consumed by producing a complex with CRP and enzymatically modified low density lipoprotein and then complement levels decreased. 5) In ischemia, plasma complement levels reach maximum levels in the first three hours and then start to decrease due to consumption. Later, complement is locally produced by the ischemic myocardium.
6) Therefore, the higher CRP levels are, the lower the C4 levels are. Also, in the present study, CRP levels were higher and C4 levels were lower in the sudden onset group than those in the preinfarction angina group. At this point of view, it can be considered that there was a lower grade inflammatory response in the preinfarction angina group. Since a lower grade immunoinflammatory response causes less necrosis, it is related to the beneficial effect of preinfarction angina.
Only IgE of all the immunoglobulins analyzed was statistically higher in the preinfarction angina group. Previous studies demonstrated that IgE levels increase in acute coronary syndromes. 7, 8, 33) Also, in the some of the studies, a high level of IgE was considered to protect the patients from complications occurring during MI due to depressed platelet function, impaired thrombinogenesis, and depression of clot formation. Szczeklik, et al 8) indicated that IgE levels must be higher than 200 kU/L for a protective effect. Also, in our study, IgE levels were found to be higher than 200 kU/L in the preinfarction angina group. Because IgE causes the thrombi to be less resistant to fibrinolysis, it causes a beneficial effect in post infarct angina patients. Adreotti, et al 34) observed that thrombolytic therapy results in more rapid reperfusion and a smaller infarct size in patients with preinfarction angina. They concluded that this effect is dependent on faster coronary thrombolysis in addition to, or perhaps instead of, preconditioning. Ishihara, et al 35) confirmed that reperfusion was more frequently achieved in patients with preinfarction angina. On the other hand, an increase in IgE levels is seen together with an increase in interleukin 4 levels. 36, 37) When IL4 levels are high, tumor necrosis factor, interleukin-1, and interleukin-2 are suppressed.
38) The suppression of these cytokines, which are proinflammatory molecules, attenuates the severity of the inflammatory response. Tissue hypoxia and necrosis are decreased in the site where the inflammatory response is decreased. In our study, in the preinfarction angina group, different from the sudden onset group, some immunoinflammatory parameters such as CRP and WBC whose high levels are related to a poor prognosis, decreased, whereas IgE and C4, whose high levels are related to a good prognosis, increased. Thus, it may be speculated that preinfarction angina can invoke protective immune mechanisms.
In conclusion, the beneficial effect of preinfarction angina may be associated with an immunoinflammatory response modified by a brief ischemic episode occurring before myocardial infarction. Further detailed studies are required to determine whether these findings would be confirmed in large clinical trials.
